Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Oral Oncol. 2013 Aug 27;49(10):1025–1031. doi: 10.1016/j.oraloncology.2013.07.009

Figure 5.

Figure 5

(A) Proportion of patients with Grade 2+ or Grade 3+ mucositis during treatment (week 1-9) and follow-up (weeks 11-14) using NCI-CTCAE 3.0. (B) Proportion of patients with Grade 2+ or Grade 3+ Dermatitis during treatment (weeks 1-9) and follow up (weeks 11-14).